Self-limited epilepsy with centrotemporal spikes (SeLECTS / Rolandic epilepsy)

What it is

SeLECTS — the name endorsed by the 2022 ILAE classification of childhood epilepsy syndromes — replaces the older term 'benign childhood epilepsy with centrotemporal spikes' (BECTS) and 'benign Rolandic epilepsy'. The change reflects two things: that the seizures themselves are not always 'benign' in their consequences (subtle language and attention effects exist in a subset of children), and that the central feature is the highly characteristic centrotemporal sharp wave on EEG rather than a precise location in the Rolandic strip.

Children are otherwise developing normally and there is often a family history of febrile seizures, SeLECTS or other self-limited focal epilepsies. The underlying biology is a maturational hyper-excitability around the central-temporal region that the child grows out of.

How it presents

Seizures are nearly always nocturnal — typically in the first hour of sleep or just before waking. A classic event involves several of:

• Twitching, numbness or pulling of one side of the face — corner of the mouth, cheek or tongue
• Excessive drooling and gurgling, choking-like sounds
• Inability to speak (the child wants to call out but cannot articulate) — but understanding is preserved
• Sensation in the tongue or inner cheek of one side
• Spread to the ipsilateral arm or even the whole side (hemifacial-hemiclonic seizure)
• Occasional secondary generalisation to a brief tonic-clonic seizure
• Awareness is often preserved at the start; the seizure usually lasts 1–3 minutes

Diagnosis

The diagnosis combines a typical history with a characteristic EEG. The EEG shows high-amplitude (often >200 µV) di-phasic sharp waves localised to the centrotemporal regions — frequently bilateral, often with a horizontal dipole — that are markedly activated by drowsiness and sleep. If awake EEG is normal, a sleep-deprived recording is highly likely to confirm the abnormality. Background activity is normal.

MRI of the brain is performed once at diagnosis to exclude structural mimics (cortical dysplasia, low-grade tumours) and is, by definition, normal in SeLECTS.

A small proportion of children have atypical evolutions — most importantly, electrical status epilepticus in sleep (ESES / CSWS) and Landau-Kleffner syndrome, which present with a sudden dip in language or learning and a markedly active EEG in slow-wave sleep. These atypical evolutions are uncommon (perhaps 1–3% of SeLECTS cases) but important to recognise because they may need more intensive treatment.

Treatment

Because seizures are infrequent, nocturnal, and self-limited, the threshold for starting daily medication is high. Many children — perhaps the majority — are managed with a written safety plan and a rescue medication rather than daily antiseizure treatment. Decisions are individualised:

• No daily medication for a child who has had a single typical nocturnal seizure with a confirmatory EEG and a normal MRI. A buccal/intranasal midazolam rescue plan covers prolonged events.
• Daily medication when seizures are recurrent or disruptive to family life (multiple events per month, daytime seizures, hemiclonic events affecting the dominant side, secondary generalisation). Levetiracetam, oxcarbazepine, carbamazepine and lamotrigine are all reasonable choices; valproate is highly effective but generally avoided in girls of childbearing potential. Sulthiame is widely used in continental Europe.
• Sodium-channel blockers (carbamazepine, oxcarbazepine, phenytoin) occasionally worsen the EEG and seizures in a small subgroup — this is one of the recognised atypical evolutions; in that situation, levetiracetam or sulthiame are preferred.
• Atypical evolutions (ESES, Landau-Kleffner) need urgent specialist input and usually a different treatment strategy (steroids, sulthiame, benzodiazepines or surgery for selected lesional cases).
• Regular review of attention, language and learning is part of care: a meaningful minority of children with SeLECTS have subtle, often transient difficulties with reading, attention and working memory, which usually improve as the EEG settles.

Prognosis

The outlook is excellent. Seizures remit by mid-adolescence (usually 14–16 years) in essentially every child, the great majority without ever needing more than one or two short courses of medication. Adult outcomes for learning, employment and quality of life mirror the general population in most studies. A small minority retain subtle attentional or language effects, and an even smaller minority develop other epilepsy types later — these atypical evolutions are the reason long-term reassurance is given alongside age-appropriate follow-up rather than absolute promises.

How an educational review can help

Many parents reach a clinic frightened by a nocturnal hemifacial-clonic episode and unsure why their child does not need a daily tablet. An educational review can explain the EEG, place the case against the 2022 ILAE classification, weigh the case for and against daily medication, set out a clear rescue plan, and outline what to watch for as the child grows.

It is an educational second opinion — not a diagnosis, treatment or prescription — and it does not replace the care of your child's own clinicians.